The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.
 
Sunil Verma
Leadership - Oncology Education
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Novartis; Pfizer; Roche/Genentech; Spectrum Pharmaceuticals
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Hanmi; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca
 
Jungsil Ro
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Marco Colleoni
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Celldex; OBI Pharma; Pfizer; Pierre Fabre; Puma Biotechnology
 
Shailendra Verma
No Relationships to Disclose
 
Patrick Schnell
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Eustratios Bananis
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Dongrui (Ray) Lu
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Johannes Ettl
Honoraria - Lilly; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Speakers' Bureau - Celgene; Lilly; Pfizer; Roche; Teva
Travel, Accommodations, Expenses - Celgene; Pfizer; Teva
 
Massimo Cristofanilli
Honoraria - Dompé Farmaceutici; Pfizer
Consulting or Advisory Role - Dompé Farmaceutici; Newomics; Vortex Biosciences
 
Hope S. Rugo
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
Speakers' Bureau - Genomic Health
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)